Advances in preclinical evaluation of experimental antibody-drug conjugates

Abstract

The ability to chemically modify monoclonal antibodies with the attachment of specific functional groups has opened up an enormous range of possibilities for the targeted treatment and diagnosis of cancer in the clinic. As the number of such antibody-based drug candidates has increased, so too has the need for more stringent and robust preclinical evaluation of their in vivo performance to maximize the likelihood that time, research effort, and money are only spent developing the most effective and promising candidate molecules for translation to the clinic. Concurrent with the development of antibody-drug conjugate (ADC) technology, several recent advances in preclinical research stand to greatly increase the experimental rigor by which promising candidate molecules can be evaluated. These include advances in preclinical tumor modeling with the development of patient-derived tumor organoid models that far better recapitulate many aspects of the human disease than conventional subcutaneous xenograft models. Such models are amenable to genetic manipulation, which will greatly improve our understanding of the relationship between ADC and antigen and stringently evaluate mechanisms of therapeutic response. Finally, tumor development is often not visible in these in vivo models. We discuss how the application of several preclinical molecular imaging techniques will greatly enhance the quality of experimental data, enabling quantitative pre- and post-treatment tumor measurements or the precise assessment of ADCs as effective diagnostics. In our opinion, when taken together, these advances in preclinical cancer research will greatly improve the identification of effective candidate ADC molecules with the best chance of clinical translation and cancer patient benefit.

Keywords

Antibody-drug conjugate / tumor / preclinical / organoid / CRISPR / preclinical imaging / theranostic

References

[1] Hudis CA.Trastuzumab--mechanism of action and use in clinical practice.N Engl J Med2007;357:39-51

[2] Ulaner GA,Ross DS.Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT.J Nucl Med2016;57:1523-8 PMCID:PMC5050126

[3] Wong CH,Lo AW.Estimation of clinical trial success rates and related parameters.Biostatistics2019;20:273-86 PMCID:PMC6409418

[4] Wouters OJ,Luyten J.Estimated research and development investment needed to bring a new medicine to market, 2009-2018.JAMA2020;323:844-53 PMCID:PMC7054832

[5] Hingorani AD,Finan C.Improving the odds of drug development success through human genomics: modelling study.Sci Rep2019;9:18911 PMCID:PMC6906499

[6] Maeda H.Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.Adv Drug Deliv Rev2015;91:3-6

[7] Shoemaker RH.The NCI60 human tumour cell line anticancer drug screen.Nat Rev Cancer2006;6:813-23

[8] Tuveson D.Cancer modeling meets human organoid technology.Science2019;364:952-5

[9] Mullenders J,Brousali A.Mouse and human urothelial cancer organoids: a tool for bladder cancer research.Proc Natl Acad Sci U S A2019;116:4567-74 PMCID:PMC6410883

[10] Sachs N,Kopper O.A living biobank of breast cancer organoids captures disease heterogeneity.Cell2018;172:373-386.e10

[11] Tiriac H,Engle DD.Organoid profiling identifies common responders to chemotherapy in pancreatic cancer.Cancer Discov2018;8:1112-29 PMCID:PMC6125219

[12] HCMI. Available from: https://www.atcc.org/Products/Cells%20and%20Microorganisms/HCMI.aspx [Last accessed on 7 Jul 2021]

[13] Sahai E,Cukierman E.A framework for advancing our understanding of cancer-associated fibroblasts.Nat Rev Cancer2020;20:174-86 PMCID:PMC7046529

[14] Biffi G,Spielman B.IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma.Cancer Discov2019;9:282-301 PMCID:PMC6368881

[15] Miyabayashi K,Deschênes A.Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes.Cancer Discov2020;10:1566-89 PMCID:PMC7664990

[16] Capecchi MR.Altering the genome by homologous recombination.Science1989;244:1288-92

[17] Sandy P,Jacks T.Mammalian RNAi: a practical guide.Biotechniques2005;39:215-24

[18] Stegmeier F,Rickles RJ,Elledge SJ.A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.Proc Natl Acad Sci U S A2005;102:13212-7 PMCID:PMC1196357

[19] Adli M.The CRISPR tool kit for genome editing and beyond.Nat Commun2018;9:1911 PMCID:PMC5953931

[20] Loew R,Hampf M,Gossen M.Improved Tet-responsive promoters with minimized background expression.BMC Biotechnol2010;10:81 PMCID:PMC3002914

[21] Koga S,Honkura N.In vivo subcellular imaging of tumors in mouse models using a fluorophore-conjugated anti-carcinoembryonic antigen antibody in two-photon excitation microscopy.Cancer Sci2014;105:1299-306 PMCID:PMC4462348

[22] Rice BW.The importance of being red.Nat Biotechnol2009;27:624-5

[23] Li R,Prytyskach M,Weissleder R.Single-cell intravital microscopy of trastuzumab quantifies heterogeneous in vivo kinetics.Cytometry A2020;97:528-39 PMCID:PMC7028488

[24] Voskuil FJ,Hooghiemstra WTR.Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: A quantitative dose-escalation study.Theranostics2020;10:3994-4005 PMCID:PMC7086353

[25] Renier N,Simon DJ,Ariel P.iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging.Cell2014;159:896-910

[26] Weber J,Bohndiek SE.Contrast agents for molecular photoacoustic imaging.Nat Methods2016;13:639-50

[27] Zhang C,Hong K,Wan J.Photoacoustic and fluorescence imaging of cutaneous squamous cell carcinoma in living subjects using a probe targeting integrin α_vβ₆.Sci Rep2017;7:42442 PMCID:PMC5299425

[28] Yoon JK,Ryu EK,Lee SJ.Current perspectives on ⁸⁹Zr-PET imaging.Int J Mol Sci2020;21:E4309 PMCID:PMC7352467

[29] Wu AM.Engineered antibodies for molecular imaging of cancer.Methods2014;65:139-47 PMCID:PMC3947235

[30] Carter KP,Lohrey TD.Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals.Commun Chem2020;3

[31] Lyons SK,Brindle KM.Imaging mouse cancer models in vivo using reporter transgenes.Cold Spring Harb Protoc2013;2013:685-99

[32] Yao Z,Prescher JA.Advances in bioluminescence imaging: new probes from old recipes.Curr Opin Chem Biol2018;45:148-56 PMCID:PMC6076869

[33] Vandergaast R,Jiang H.Enhanced noninvasive imaging of oncology models using the NIS reporter gene and bioluminescence imaging.Cancer Gene Ther2020;27:179-88 PMCID:PMC7170803